214470-66-3

Basic information

• Product Name: 3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-hydroxy-6-Methoxy-
• Synonyms: 3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-hydroxy-6-Methoxy-;7-(3-chloropropoxy)-4-hydroxy-6-methoxyquinoline-3-carbonitrile;7-(3-Chloropropoxy)-4-hydroxy-6-methoxy-3-quinolinecarbonitrile
• CAS NO: 214470-66-3
• Molecular Formula: C₁₄H₁₃ClN₂O₃
• Molecular Weight: 292.71762
• Mol File: 214470-66-3.mol

Chemical Properties

• Boiling Point: 506.4°C at 760 mmHg
• Flash Point: 260.1°C
• Appearance: /
• Density: 1.37g/cm³
• Vapor Pressure: 7.04E-11mmHg at 25°C
• Refractive Index: 1.623
• PKA: 1.02±0.50(Predicted)
• CAS DataBase Reference: 3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-hydroxy-6-Methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-hydroxy-6-Methoxy-(214470-66-3)
• EPA Substance Registry System: 3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-hydroxy-6-Methoxy-(214470-66-3)

Safety Data

• Hazardous Substances Data: 214470-66-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-hydroxy-6-Methoxyis used as a key intermediate in the synthesis of Bosutinib (B676095), an anticancer medication. The compound plays a crucial role in the development of this drug, which targets specific tyrosine kinases involved in cancer cell growth and proliferation.
Application Reason:
The compound's unique structure allows it to be a valuable building block in the synthesis of Bosutinib, a potent inhibitor of BCR-ABL and Src kinases. By incorporating this compound into the drug's structure, researchers can develop a medication that effectively targets cancer cells and helps in the treatment of various types of cancer.

InChI:InChI=1/C14H13ClN2O3/c1-19-12-5-10-11(6-13(12)20-4-2-3-15)17-8-9(7-16)14(10)18/h5-6,8H,2-4H2,1H3,(H,17,18)

Upstream product

• 20428-58-4 α-lithioacetonitrile 
• 1637593-19-1 3-(2-amino-4-(3-chloropropoxy)-5-methoxyphenyl)-3-oxopropanenitrile 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 151719-68-5 4-(3-Chloropropoxy]-3-methoxybenzoic acid 
• 1637593-17-9 ethyl 3-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-2-cyano-3-oxopropanoate 
• 1637593-18-0 3-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-oxopropanenitrile 
• 1637593-16-8 4-(3-chloropropoxy)-5-methoxy-2-nitrobenzoyl chloride 
• 214470-57-2 methyl 4-(3-chloropropoxy)-5-methoxy-2-nitrobenzoate 
• 214470-59-4 2-Amino-4-(3-chloro-propoxy)-5-methoxy-benzoic acid methyl ester 
• 111627-40-8 methyl 4-(3-chloropropoxy)-3-methoxybenzoate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 

Downstream Products

• 214470-68-5 7-(3-chloro-propoxy)-4-chloro-6-methoxy-quinoline-3-carbonitrile 

Relevant articles and documents

A new and practical synthesis of 7-(3-chloropropoxy)-6-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile

New and improved synthetic route of bosutinib intermediate 7-(3-chloropropoxy)-6-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3) is described on a hectogram scale. An intramolecular cyclization of 3-(2-aminophenyl)-3-oxopropanenitrile 11 with DMF-DM

Synthesis and structure-activity relationships of 3-cyano-4(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors

A series of 3-cyano-4-(phenoxyanilino)cyanoquinolines has been prepared as MEK (MAP kinase kinase) inhibitors. The best activity is seen with alkoxy groups at both the 6- and 7-positions. The lead compounds show low nanomolar IC50's against MAP kinase kinase, and have potent inhibitory activity in tumor cells. (C) 2000 Elsevier Science Ltd.